Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer

被引:39
|
作者
Adashek, Jacob J. [1 ]
Jain, Rohit K. [2 ]
Zhang, Jingsong [2 ]
机构
[1] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Internal Med, Tampa, FL 33612 USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Genitourinary Oncol, 12902 USF Magnolia Dr, Tampa, FL 33612 USA
关键词
PARP inhibitors; DNA damage repair deficiency; prostate cancer; targeted therapy; DNA-REPAIR; POLY(ADP-RIBOSE) POLYMERASE; MAINTENANCE THERAPY; OVARIAN-CANCER; MUTANT-CELLS; OLAPARIB; NIRAPARIB; DEFECTS; TUMORS; BRCA2;
D O I
10.3390/cells8080860
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The approval of upfront abiraterone for castration-sensitive prostate cancer and the approval of enzalutamide and apalutamide for non-metastatic castration-resistant prostate cancer have led to early utilization of potent androgen receptor (AR) signaling inhibitors in treating advanced prostate cancer. There is an unmet need to develop novel therapies beyond targeting AR signaling for metastatic castration-resistant prostate cancer (mCRPC). Poly (ADP-ribose) polymerase inhibitors (PARPi) belong to a class of targeted agents being developed for the treatment of homologous recombination repair (HRR) deficient tumors. Olaparib, rucaparib, niraparib, veliparib, and talazoparib were evaluated in early phase trials as a monotherapy for HRR-deficient mCRPC. Among them, olaparib and rucaparib have breakthrough designations for BRCA1/2-mutated mCRPC. Phase II studies also reported clinical activity of the PARPi and abiraterone combination and the PARPi checkpoint inhibitor combination in HRR-intact mCRPC. Ongoing phase III trials are testing these combinations as frontline or later line treatments for mCRPC. This review summarizes the critical clinical data as well as ongoing clinical trials for developing PARPi in treating mCRPC.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
    Hussain, Maha
    Mateo, Joaquin
    Fizazi, Karim
    Saad, Fred
    Shore, Neal
    Sandhu, Shahneen
    Chi, Kim N.
    Sartor, Oliver
    Agarwal, Neeraj
    Olmos, David
    Thiery-Vuillemin, Antoine
    Twardowski, Przemyslaw
    Roubaud, Guilhem
    Ozguroglu, Mustafa
    Kang, Jinyu
    Burgents, Joseph
    Gresty, Christopher
    Corcoran, Claire
    Adelman, Carrie A.
    de Bono, Johann
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (24): : 2345 - 2357
  • [42] Trial design for metastatic castration-resistant prostate cancer
    Sonpavde, Guru
    Fleming, Mark T.
    Hutson, Thomas E.
    Galsky, Matthew D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (21) : 3647 - 3648
  • [43] Drug therapies for metastatic castration-resistant prostate cancer
    El-Bahesh, Ehab
    Finianos, Antoine
    Alfaraj, Abeer
    Aragon-Ching, Jeanny B.
    FUTURE ONCOLOGY, 2015, 11 (17) : 2395 - 2403
  • [44] Re: Olaparib for Metastatic Castration-resistant Prostate Cancer
    Di Lorenzo, Giuseppe
    Autorino, Riccardo
    EUROPEAN UROLOGY, 2020, 78 (05) : 767 - 768
  • [45] Contemporary management of metastatic castration-resistant prostate cancer
    Sonpavde, Guru
    Sternberg, Cora N.
    CURRENT OPINION IN UROLOGY, 2011, 21 (03) : 241 - 247
  • [46] Histologic Spetrum of Metastatic Castration-Resistant Prostate Cancer
    Huang, Jiaoti
    Yin, Yu
    Thomas, George
    True, Lawrence
    Beer, Tomasz M.
    Gleeve, Martin
    Witte, Owen
    Stuart, Josh
    Evans, Chris
    Foye, Adam
    Youngren, Jack
    Small, Eric
    LABORATORY INVESTIGATION, 2017, 97 : 231A - 231A
  • [47] The obesity paradox in metastatic castration-resistant prostate cancer
    Martini, Alberto
    Shah, Qainat N.
    Waingankar, Nikhil
    Sfakianos, John P.
    Tsao, Che-Kai
    Necchi, Andrea
    Montorsi, Francesco
    Gallagher, Emily J.
    Galsky, Matthew D.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2022, 25 (03) : 472 - 478
  • [48] Drug resistance in metastatic castration-resistant prostate cancer
    Bostjan Seruga
    Alberto Ocana
    Ian F. Tannock
    Nature Reviews Clinical Oncology, 2011, 8 : 12 - 23
  • [49] Re: Olaparib for Metastatic Castration-resistant Prostate Cancer
    Cumberbatch, Marcus
    Condon, Benjamin
    Lawrentschuk, Nathan
    Murphy, Declan G.
    EUROPEAN UROLOGY, 2021, 79 (02) : 319 - 320
  • [50] Monitoring of treatment for metastatic castration-resistant prostate cancer
    Hinz, Stefan
    AKTUELLE UROLOGIE, 2017, 48 (03) : 225 - 229